Adaptions and Resiliency to Multi-Stressor OpeRations

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-15

Study Completion Date

2026-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non-combat-related muscle, tendon and bone injuries are the most common injuries suffered by military personnel, particularly in new recruits. These injuries impact military readiness and are responsible for roughly 60% of limited duty days, 65% of soldiers who are unable to deploy, and nearly $500 million in medical cost to the government annually in the Army alone. Drug interventions must be studied and developed to prevent these negative outcomes and prepare military personnel for the demands of military service. At the current time, military leadership has identified critical gaps in understanding how to minimize these injuries and train soldiers with drug intervention serving among those gaps.

The goal of this study is to determine how a hormonal intervention can change muscle, tendon, and bone function as well as physical and psychological performance in response to mental and physical stress. To do so, we will examine sex hormone (testosterone, estrogen) levels, muscle, tendon, and bone images, blood samples, and physical and mental performance. We will look at things like changes in hormone levels, chemicals released from active skeletal muscles, and your body composition. The results from this study will be used to improve physical readiness training in the military with the goal of reducing injuries.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population

NCT06247267

Hypogonadism Gender Identity Dysphoria

RECRUITING

Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer

NCT00167648

Cancer Prostate Neoplasms

COMPLETED PHASE2

Impact of Estradiol Addback

NCT01862835

Normal Healthy Volunteers

COMPLETED PHASE1

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

NCT01201863

Endocrine Dysfunction Trauma Brain Injury

COMPLETED PHASE4

Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents

NCT03864913

Health Services for Transgender Persons Transgender Persons

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Suppression of the reproductive hypothalamic-pituitary-gonadal (HPG) axis is a common physiological response to strenuous military training and can be difficult to replicate in simulated environments. Additionally, whether HPG suppression contributes to the physiological changes, performance decrements, and high MSK injury risk associated with multi-stressor military training is unknown. Thus, we will utilize pharmacological inhibition of the HPG axis to test if estrogen and testosterone replacement will mitigate injury risk and performance decrements following military-relevant multi-stressor training. This project aims to deliver a state-of-the-art evaluation of male and female adaptive responses to multi-stressor training and evidence-based guidance for the safe and ethical use of exogenous hormone replacement as a MSK injury mitigation solution during multi-stressor training and operations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Musculoskeletal Injury Hypogonadism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CONTROL (men + women)

The control group will maintain their habitual exercise, diet, and sleep patterns, all of which will be monitored throughout the study.

Group Type NO_INTERVENTION

No interventions assigned to this group

STRESS (men + women): Multi-Stressor Training

Research volunteers will be randomized into the stress exposure group (STRESS) will undergo a 4-week exercise training program consisting of 5 consecutive days of strenuous physical training followed by 2 days of recovery (energy balance, no structured exercise). The exercise training program will consist of military-relevant physical training exercises (e.g., load carriage, aerobic and resistance exercises) that progressively increase in duration and intensity to increase exercise energy expenditure. Participants will perform multiple exercises per day using a variety of endurance and muscle loading modalities designed to mimic movements typically observed during real-life military operations.

Group Type ACTIVE_COMPARATOR

Multi-Stressor Training

Intervention Type OTHER

A 4-week physical training program that mimics military training.

SUPPRESS (men): Multi-Stressor Training + Zoladex + AndroGel 1.25g

In addition to participating in the multi-stressor training program, male participants randomized to the GnRH suppressed (SUPPRESS) group will be administered a long-acting GnRH agonist (Zoladex) by trained medical professionals to suppress endogenous gonadal steroids. Following GnRH agonist administration, men will be administered 1.25g/day (SUPPRESS) of topical 1% testosterone gel (AndroGel, Abbvie, North Chicago, IL) to be applied to the shoulders, upper arms, and/or stomach area daily.

Group Type EXPERIMENTAL

Goserelin 3.6 MG

Intervention Type DRUG

Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.

Multi-Stressor Training

Intervention Type OTHER

A 4-week physical training program that mimics military training.

Testosterone gel (AndroGel 1.25g)

Intervention Type DRUG

Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).

SUPPRESS (women): Multi-stressor training + Zoladex + Placebo patch

In addition to participating in the multi-stressor training program, male participants randomized to the GnRH suppressed (SUPPRESS) group will be administered a long-acting GnRH agonist (Zoladex) by trained medical professionals to suppress endogenous gonadal steroids. Following GnRH agonist administration, women in the SUPRESS group will receive a placebo transdermal patch.

Group Type EXPERIMENTAL

Goserelin 3.6 MG

Intervention Type DRUG

Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.

Multi-Stressor Training

Intervention Type OTHER

A 4-week physical training program that mimics military training.

Placebo Patch

Intervention Type DRUG

Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.

REPLACE (men): Multi-Stressor Training + Zoladex + AndroGel 5g

Following GnRH agonist administration, men will be administered 5g/day (REPLACE) of topical 1% testosterone gel (AndroGel, Abbvie, North Chicago, IL) to be applied to the shoulders, upper arms, and/or stomach area daily.

Group Type EXPERIMENTAL

Goserelin 3.6 MG

Intervention Type DRUG

Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.

Multi-Stressor Training

Intervention Type OTHER

A 4-week physical training program that mimics military training.

Testosterone gel (AndroGel 5g)

Intervention Type DRUG

Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).

REPLACE (women): Multi-Stressor Training + Zoladex + Climara Pro Patch

Following GnRH agonist administration, women, the REPLACE group will receive a transdermal estradiol (0.045 mg/day) + levonorgestrel (0.015 mg/day) patch (Climara Pro, Bayer, NJ) to be placed on a clean, dry area of the skin on the lower

Group Type EXPERIMENTAL

Goserelin 3.6 MG

Intervention Type DRUG

Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.

Multi-Stressor Training

Intervention Type OTHER

A 4-week physical training program that mimics military training.

Estradiol / Levonorgestrel Transdermal System [Climara Pro]

Intervention Type DRUG

Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Goserelin 3.6 MG

Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.

Intervention Type DRUG

Multi-Stressor Training

A 4-week physical training program that mimics military training.

Intervention Type OTHER

Testosterone gel (AndroGel 5g)

Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).

Intervention Type DRUG

Testosterone gel (AndroGel 1.25g)

Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).

Intervention Type DRUG

Estradiol / Levonorgestrel Transdermal System [Climara Pro]

Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.

Intervention Type DRUG

Placebo Patch

Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zoladex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-40 years
2. body mass index (BMI) 18-30 kg/m2
3. weight stable (±10 lbs) in past 2 months
4. takes part in moderate physical activity for at least 150 minutes/week
5. currently free of upper or lower body /extremity injury or impairment
6. able to commit to study duration
7. agrees to adhere to study requirements
8. not taking prescription medications or be willing to refrain from medication prior to and throughout the study period, unless approved by study physician
9. in men, total testosterone concentration within normal physiological range (300-1000 ng/dL)
10. in women, eumenorrheic (cycles of 26-35 days) and not using hormonal contraceptives for previous 3 months

Exclusion Criteria

1. Current smoker
2. current clinical diagnosis of an eating disorder
3. use of medication incompatible with measurement of reproductive and metabolic hormones or which may interfere with any of the study outcomes
4. current oligo/amenorrhea in women
5. any metabolic or endocrine disease
6. has been diagnosed with a medical condition, physical or psychological, that currently prevents potential subjects from exercising
7. currently pregnant or becomes pregnant during the study
8. history of heart condition OR high blood pressure
9. treating physician requires subject participates in medically supervised physical activity only
10. history of drug addiction, or regular use of recreational drugs
11. currently undergoing treatment for or have a history of mental health conditions
12. irregular lab results (e.g., PSA \>3 ng/mL)
13. Current diagnoses of disorders known to affect bone metabolism including hyperthyroidism, hyperparathyroidism, osteomalacia, Cushing's, diabetes mellitus or renal insufficiency
14. Current use of medications known to affect bone metabolism including estrogens, androgens, anti-estrogens, bisphosphonates (oral bisphosphonates within one year of the baseline visit or IV bisphosphonates within three years of the baseline visit), calcitonin, fluoride, oral or inhaled glucocorticoids, suppressive doses of thyroxine, lithium, pharmacological doses of vitamin D (greater than 2000 IU/day), anti-convulsants, depot medroxyprogesterone within 6 months.
15. History of deep vein thrombosis, pulmonary embolism, or clotting disorders.
16. History of stroke or myocardial infarction
17. Serum 25-hydroxyvitamin D \< 20 ng/mL
18. Thyroid dysfunction
19. Serum creatinine \> 2 mg/dL
20. Personal history or history of a first-degree relative with breast cancer
21. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2x the upper limit of normal
22. Serum bilirubin \> 2 mg/dL
23. Serum alkaline phosphatase \> 150 U/L
24. Plasma hemoglobin \< 10 gm/dL
25. Hematocrit \> 50
26. Fracture within the last 6 months.
27. Serum testosterone level \< 270 or \> 1070 ng/dL
28. Systolic blood pressure \> 160 or diastolic blood pressure \> 95
29. Active substance abuse
30. Triglycerides \> 150 fasting
31. History of hereditary angioedema
32. History of chest pain at rest, during daily activities of living, or when performing physical activity
33. Musculoskeletal injury removing subject from physical activity for more than a month within the past 2 years
34. Recreational drug use more than 2 times per month in each of the previous 6 months
35. Self-reported vision is worse than 20/20.
36. Personal history or history of a first-degree relative with breast cancer
37. Experienced a fracture within the last 6 months
38. participated and taken investigational drug in any other clinical trial (including bioequivalence study) within six months prior to study drug administration
39. Diagnosed with eating disorder
40. Have food allergies, intolerance, restriction, or special diet needs
41. History of endometriosis
42. Current diagnosis of reproductive health issues, such as ovarian cysts, PCOS, pelvic lesions, undiagnosed ovarian enlargement
43. Have undiagnosed abnormal vaginal bleeding
44. Currently breastfeeding or within 2 months after stopping breastfeeding
45. Have dietary restrictions

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes